BAC consensus conference, November 4-6, 2004: Epidemiology, pathogenesis, and preclinical models

Journal of Thoracic Oncology

Volumn 1, Issue 9 SUPPL., 2006, Pages

  Christiani, David C ^a   Pao, William ^b   DeMartini, James C ^c   Linnoila, R Ilona ^d   Malkinson, Alvin M ^e   Onn, Amir ^f   Politi, Katerina A ^b   Sharp, Michael ^g   Kim, Kwok ^h  

^a HARVARD UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g VETERINARY LABORATORIES AGENCY   (United Kingdom)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bronchioloalveolar carcinoma; Epidemiology; Lung cancer; Pathogenesis; Preclinical models

Indexed keywords

ERLOTINIB; GEFITINIB;

ADENOMA; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL INTERACTION; CONFERENCE PAPER; DNA SEQUENCE; ENZYME ACTIVITY; ETHNICITY; GENE EXPRESSION; GENE MUTATION; GENETIC ENGINEERING; GENETIC HETEROGENEITY; HETEROZYGOSITY; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LEUKOCYTE; LUNG ALVEOLUS CELL CARCINOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SMOKING; STROMA CELL; TIME SERIES ANALYSIS; TUMOR CLASSIFICATION; ADENOCARCINOMA; ANIMAL; CANCER STAGING; CONSENSUS DEVELOPMENT; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; MOUSE; NEEDLE BIOPSY; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SHEEP; TRANSGENIC MOUSE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANIMALS; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SHEEP;

EID: 34247844546     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/s1556-0864(15)30002-2     Document Type: Conference Paper

References (79)

1. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural Tumors, 3rd. Berlin: Springer Verlag, 1999.
2. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002;74:1640-1646.
3. Grossman DA, Hiti AL, McNiel EA, Ye Y, Alpaugh ML, Barsky SH. Comparative oncological studies of feline bronchioloalveolar lung carcinoma, its derived cell line and xenograft. Cancer Res 2002;62:3826-3833.
4. Hahn FF, Muggenburg BA, Griffith WC. Primary lung neoplasic in a beagle colony. Vet Pathol 1996;33:633-638.
5. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994;73:1163-1170.
6. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 2004;22:1103-1109.
7. Miller VA, Patel J, Shah N, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioalveloar cell carcinoma (BAC): preliminary results of a phase II trial (Abstract). Proc Amer Soc Clin Onc 2003:2491.
8. West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc Am Soc Clin Oncol 2004;22:7014.
9. Milton DT, Kris MG, Gomez JE, Feinstein MB. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Support Care Cancer 2005;13:70-72.
10. Falk RT, Pickle LW, Fonthan ET, et al. Epidemiology of bronchioalveolar carcinoma. Cancer Epidemiol Biomark Prevent 1992;1:339-344.
11. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
12. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinoma: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996;179:254-259.
13. Marchetti A, Pellegrini S, Bertacca G, et al. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. J Pathol 1998;184:240-246.
14. Koga T, Hashimoto S, Sugio K, et al. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinomas. Clin Cancer Res 2001;7:1730-1738.
15. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. Virchows Arch 2002;440:598-603.
16. Dacic S, Sasatomi E, Swalsky PA, Kim DW, Finkelstein SD, Yousem SA. Loss of heterozygosity patterns of sclerosing hemangioma of the lung and bronchioloalveolar carcinoma indicate a similar molecular pathogenesis. Arch Pathol Lab Med 2004;128:880-884.
17. Sasatomi E, Johnson LR, Aldeeb DN, Lomago DM, Thompson JW Jr. Genetic profile of cumulative mutational damage associated with early pulmonary adenocarcinoma: bronchioloalveolar carcinoma vs. stage I invasive adenocarcinoma. Am J Surg Pathol 2004;28:1280-1288.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
20. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
21. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-865.
22. Bonne C. Morphological resemblance of pulmonary adenomatosis (jaagsiekte) in sheep and certain cases of cancer of the lung in man. Am J Cancer 1939;35:491.
23. Jaagsiekte sheep retrovirus and lung cancer. In Fan H (Ed.), Current Topics in Microbiology and Immunology. Berlin: Springer-Verlag, 2003.
24. Palmarini M, Fan H. Retrovirus-induced ovine pulmonary adenocarcinoma, an animal model for lung cancer. J Natl Cancer Inst 2001;93:1603-1614.
25. Sharp JM, DeMartini JC. Natural history of JSRV in sheep. Curr Top Microbiol Immunol 2003;275:55-79.
26. York DF, Vigne R, Verwoerd DW, Querat G. Nucleotide sequence of the jaagsiekte retrovirus, an exogenous and endogenous type D and B retrovirus of sheep and goats. J Virol 1992;66:4930-4939.
27. DeMartini JC, Bishop JV, Allen TE, et al. Jaagsiekte sheep retrovirus proviral clone JSRV(JS7), derived from the JS7 lung tumor cell line, induces ovine pulmonary carcinoma and is integrated into the surfactant protein A gene. J Virol 2001;75:4239-4246.
28. Platt JA, Kraipowich N, Villafane F, DeMartini JC. Alveolar type II cells expressing jaagsiekte sheep retrovirus capsid protein and surfactant proteins are the predominant neoplastic cell type in ovine pulmonary adenocarcinoma. Vet Pathol 2002;39:341-352.
29. Bai J, Bishop JV, Carlson JO, DeMartini JC. Sequence comparison of JSRV with endogenous proviruses: envelope genotypes and a novel ORF with similarity to a G-protein-coupled receptor. Virology 1999;258:333-343.
30. Fan H, Palmarini M, DeMartini JC. Transformation and oncogenesis by jaagsiekte sheep retrovirus. Curr Top Microbiol Immunol 2003;275:139-177.
31. Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, Lerman MI, Miller AD. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci U S A 2001;98:4443-4448.
32. Maeda N, Palmarini M, Murgia C, Fan H. Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc Natl Acad Sci U S A 2001;98:4449-4454.
33. Allen TE, Sherrill KJ, Crispell SM, Perrott MR, Carlson JO, DeMartini JC. The jaagsiekte sheep retrovirus envelope gene induces transformation of the avian fibroblast cell line DF-1 but does not require a conserved SH2 binding domain. J Gen Virol 2002;83:2733-2742.
34. Danilkovitch-Miagkova A, Duh FM, Kuzmin I, et al. Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. Proc Natl Acad Sci U S A 2003;100:4580-4585.
35. Palmarini M, Maeda N, Murgia C, De-Fraja C, Hofacre A, Fan H. A phosphatidylinositol 3-kinase docking site in the cytoplasmic tail of the Jaagsiekte sheep retrovirus transmembrane protein is essential for envelope-induced transformation of NIH3T3 cells. J Virol 2001;75:11002-11009.
36. Zavala G, Pretto C, Chow YH, et al. Relevance of Akt phosphorylation in cell transformation induced by Jaagsiekte sheep retrovirus. Virology 2003;312:95-105.
37. Cousens C, Bishop JV, Philbey AW, et al. Analysis of integration sites of Jaagsiekte sheep retrovirus in ovine pulmonary adenocarcinoma. J Virol 2004;78:8506-8512.
38. Philbey AW, Cousens C, Bishop JV, DeMartini JC, Sharp JM. Multiclonal pattern of jaagsiekte sheep retrovirus integration sites in ovine pulmonary adenocarcinoma. Virus Res 2006;117:254-263.
39. De las Heras M, Barsky SH, Hasleton PS, et al. Evidence for a protein related immunologically to the jaagsiekte sheep retrovirus in some human lung tumours. Eur Respir J 2000;16:330-332.
40. Yousem SA, Finkelstein SD, Swalsky PA, Bakker A, Ohori NP. Absence of jaagsiekte sheep retrovirus DNA and RNA in bronchioloalveolar and conventional human pulmonary adenocarcinoma by PCR and RT-PCR analysis. Hum Pathol 2001;32:1039-1042.
41. Morozov VA, Lagaye S, Lower J, Lower R. Detection and characterization of betaretroviral sequences, related to sheep Jaagsiekte virus, in Africans from Nigeria and Cameroon. Virology 2004;327:162-168.
42. Nikitin AY, Alcaraz A, Anver MR, et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004;64:2307-2316.
43. Sunday ME, Willett CG, Graham SA, Oreffo VI, Linnoila RI, Witschi H. Histochemical characterization of non-neuroendocrine tumors and neuroendocrine cell hyperplasia induced in hamster lung by 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone with or without hyperoxia. Am J Pathol 1995;147:740-752.
44. Rehm S. Comparative aspects of pulmonary carcinogenesis. In Jones DL, Dungworth DL, Mohr U (Eds.), Respiratory System. Berlin: Springer-Verlag, 1996, pp 158-173.
45. Malkinson AM. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 1998;24:541-555.
46. Thaete IG, Nesbitt MN, Malkinson AM. Lung tumor structure among inbred strains of mice: the pulmonary adenoma histologic type (Pah) genes. Cancer Lett 1991;61:15-20.
47. Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M, Malkinson AM. Tnfa and IL-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog 2003;38:117-123.
48. Bauer AK, Malkinson AM, Kleeberger SR. Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities. Am J Physiol Cell Mol Physiol 2004;287:L685-L703.
49. Bauer AK, Dixon D, DeGraff LM, et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 2005;97:1778-1781.
50. Nuzum EO, Malkinson AM, Beer DG. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol Carcinog 1990;3:287-295.
51. Gressani KM, Leone-Kabler S, O'Sullivan MG, Case LD, Malkinson AM, Miller MS. Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. Carcinogenesis 1999;20:2159-2165.
52. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-3262.
53. Zhang Z, Wang Y, Vikis H, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Gen 2001;29:25-33.
54. Floyd HS, Farnsworth CL, Kock ND, et al. Conditional expression of the mutant Ki-ras(G12C) allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Carcinogenesis 2005;26:2196-2206.
55. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-120.
56. Jackson E, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-3248.
57. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-1116.
58. Meuwissen R, Linn S, van der Valk M, Mooi W, Berns A. Mouse model for lung tumorigenesis through Cre/Lox controlled sporadic activation of the K-Ras oncogene. Oncogene 2001;20:6551-6558.
59. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras(G12D) stimulates prolifertion and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-387.
60. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol 1997;181:401-404.
61. Sagawa M, Saito Y, Fujimura S, Linnoila RI. K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer. Br J Cancer 1998;77:720-723.
62. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996;56:2224-2228.
63. Clark J, Tichelaar J, Wert S, et al. FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. Am J Physiol Cell Mol Physiol 2001;280:L705-L715.
64. Tichelaar J, Lu W, Whitsett J. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem 2000;275:11858-11864.
65. Zhao B, Chua S, Burcin M, et al. Phenotypic consequences of lung-specific inducible expression of FGF-3. Proc Natl Acad Sci U S A 2001;98:5898-5903.
66. Ehrhardt A, Bartels T, Geick A, Klocke R, Paul D, Halter R. Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes. Br J Cancer 2001;84:813-818.
67. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989;8:98-101.
68. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-359.
69. McLemore TL, Liu MC, Blacker PC, et al. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res 1987;47:5132-5140.
70. Howard RB, Chu H, Zeligman BE, et al. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res 1991;51:3274-3280.
71. Hastings RH, Burton DW, Quintana RA, Biederman E, Gujral A, Deftos LJ. Parathyroid hormone-related protein regulates the growth of orthotopic human lung tumors in athymic mice. Cancer 2001;92:1402-1410.
72. McLemore TL, Eggleston JC, Shoemaker RH, et al. Comparison of intrapulmonary, percutaneous, intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res 1988;48:2880-2886.
73. Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierre A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 2000;6:297-304.
74. Doki Y, Muramaki K, Yamaura T, Sugiyama K, Misaki T, Saiki I. Mediastinal lymph node metastatis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer 1999;79:1121-1126.
75. Wang HY, Ross HM, Ng B, Burt ME. Establishment of an experimental intrapulmonary tumor nodule model. Ann Thorac Surg 1997;64:216-219.
76. Miyoshi T, Kondo K, Ishikura H, Kinoshita H, Matsumori Y, Monden Y. SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res 2000;20:161-163.
77. Boehle AS, Dohrmann P, Leuschner I, Kalthoff H, Henne-Bruns D. An improved orthotpoic xenotransplant procedure for human lung cancer in SCID bg mice. Ann Thorac Surg 2000;69:1010-1015.
78. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003;9:5532-5539.
79. Onn A, Isobe T, Roach JS, et al. Blockade of EGFR tyrosine kinase does not predict outcome in an orthotopic model of human lung cancer (Abstract). Proc AACR 2003;44:1076.